124
Views
12
CrossRef citations to date
0
Altmetric
Drug Profile

Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes

Pages 121-127 | Published online: 10 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Lisa Pleyer & Richard Greil. (2015) Digging deep into “dirty” drugs – modulation of the methylation machinery. Drug Metabolism Reviews 47:2, pages 252-279.
Read now
Drorit G Merkel & Arnon Nagler. (2013) The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm. Expert Review of Hematology 6:6, pages 665-676.
Read now

Articles from other publishers (10)

Galal H. Elgemeie & Reham A. Mohamed-Ezzat. 2022. New Strategies Targeting Cancer Metabolism. New Strategies Targeting Cancer Metabolism 107 142 .
Pedro Blecua, Laura Martinez‐Verbo & Manel Esteller. (2020) The DNA methylation landscape of hematological malignancies: an update. Molecular Oncology 14:8, pages 1616-1639.
Crossref
Hetty E. Carraway. (2016) Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure. Hematology 2016:1, pages 470-477.
Crossref
Hyun Ae Jung, Chi Hoon Maeng, Moonjin Kim, Sungmin Kim, Chul Won Jung & Jun Ho Jang. (2015) Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients. Oncotarget 6:18, pages 16653-16662.
Crossref
Daniel A. Pollyea & Jonathan A. Gutman. (2014) Stopping Higher-Risk Myelodysplastic Syndrome in Its Tracks. Current Hematologic Malignancy Reports 9:4, pages 421-431.
Crossref
A Valencia, E Masala, A Rossi, A Martino, A Sanna, F Buchi, F Canzian, D Cilloni, V Gaidano, M T Voso, O Kosmider, M Fontenay, A Gozzini, A Bosi & V Santini. (2013) Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia 28:3, pages 621-628.
Crossref
Junyan Lu, Xiangqian Kong, Cheng Luo & Keqin Kathy Li. (2013) Application of Epigenome-Modifying Small Molecules in Induced Pluripotent Stem Cells. Medicinal Research Reviews 33:4, pages 790-822.
Crossref
Francesca Buchi, Elena Spinelli, Erico Masala, Antonella Gozzini, Alessandro Sanna, Alberto Bosi, Germano Ferrari & Valeria Santini. (2012) Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. Leukemia Research 36:5, pages 607-618.
Crossref
Pierre Fenaux, David Bowen, Norbert Gattermann, Eva Hellström-Lindberg, Wolf-Karsten Hofmann, Michael Pfeilstöcker, Guillermo Sanz & Valeria Santini. (2010) Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion. Leukemia Research 34:11, pages 1410-1416.
Crossref
Valeria Santini. (2009) Azacitidine in lower-risk myelodysplastic syndromes. Leukemia Research 33, pages S22-S26.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.